FRANKLIN, Mass., May 12, 2011 /PRNewswire/ — PLC Systems Inc.
(OTCBB: PLCSF), a company focused on innovative medical device
technologies, today announced it will demonstrate its innovative
new product, RenalGuard®, at EuroPCR, the annual meeting of the
European Association of Percutaneous Cardiovascular Interventions
(EAPCI). More than 11,000 clinicians and medical
professionals from around the world are expected to attend this
event, which will take place in Paris, France from May 17-20,
2011.
In addition, PLC will hold its second annual international
distributor meeting, including a presentation on the
recently-announced positive results of the investigator-sponsored
REMEDIAL II clinical trial by Dr. Carlo Briguori, MD, PhD, Chief,
Laboratory of Interventional Cardiology, Clinica Mediterranea,
Naples, Italy, and Co-Director of Clinical Research, Laboratory of
Interventional Cardiology, San Raffaele Hospital, Milan, Italy, the
principal investigator of the trial. Those results indicated that
RenalGuard was more effective than the standard of care in
preventing the onset of Contrast-Induced Nephropathy (CIN) in
at-risk patients, and that its use also greatly reduced the need
for dialysis by those patients, with 4.8 percent of patients in the
control group requiring some level of dialysis compared to only 0.7
percent in the RenalGuard-treated group.
Mark R. Tauscher, president and chief executive officer of PLC
Systems, said, “CIN is a significant and growing concern worldwide,
and we are very encouraged by the prospect that RenalGuard could
prevent it. The very positive results from the REMEDIAL II trial in
Italy showed that at-risk patients treated with PLC’s RenalGuard
had a 46% lower incidence of CIN and an 85% lower rate of requiring
dialysis, both of which are clinically significant and meaningful
in terms of patient care and costs. EuroPCR, one of the
premier international cardiovascular events of the year, is a
wonderful o
‘/>”/>
